The diabetic retinopathy market is growing steadily as the prevalence of diabetes rises globally. Diabetic retinopathy (DR) is a vision-threatening complication of diabetes that damages the retinal blood vessels, potentially leading to blindness if untreated. The market includes diagnostics (screenings, imaging), therapeutics (anti-VEGF agents, steroids, implants), and surgical treatments (laser, vitrectomy).
The global diabetic retinopathy market size was valued at USD 8.51 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 13.2 Billion by 2033, exhibiting a CAGR of 5.0% during 2025-2033. North America currently dominates the market, holding a significant market share of over 43.8% in 2024, owing to its high diabetes prevalence, advanced healthcare infrastructure, and early adoption of innovative diagnostics and anti-VEGF therapies. Supportive reimbursement policies and strong R&D investment further strengthen the region’s dominance in the diabetic retinopathy market share.
Key Trends Diabetic Retinopathy Market:
Increasing adoption of AI and Tele-Ophthalmology: AI-powered screening tools and remote diagnostic platforms are enabling earlier detection of DR, especially in underserved or remote areas. These technologies help improve screening rates and reduce delays between detection and treatment.
Shift toward long-acting and sustained delivery therapies: New treatments (e.g. sustained-release implants, long-acting anti-VEGF agents) are being developed to reduce the frequency of intravitreal injections and improve patient adherence and outcomes.
Enhanced imaging & diagnostics: Innovations in imaging like optical coherence tomography (OCT), wide-field imaging, and multimodal imaging are enabling more precise detection of disease stages, including subtle or preclinical changes. Integration with AI improves diagnostic accuracy.
Greater emphasis on early intervention and screening programs: There is growing awareness (among patients, healthcare systems, governments) of the need for regular retinal exams and earlier detection to prevent progression. Mobile screening units and community outreach programs are expanding.
Accessibility improvements and cost-effectiveness: Use of biosimilars, easier-to-deploy diagnostic tools, and improvements in healthcare infrastructure are helping drive better access to diagnostics and treatments, especially in emerging markets.
Growth Drivers Diabetic Retinopathy Market:
Rising global burden of diabetes: As more people develop diabetes (especially type 2), the pool of patients at risk of DR increases. Factors like obesity, sedentary lifestyle, aging populations, and unhealthy diets contribute.
Geriatric and aging populations: Older age increases risk of retinopathy progression. As populations age globally, this raises demand for diagnostics, monitoring, and treatment.
Government & public health initiatives: National screening programs, funding for eye health, regulatory support, grants/NGO programs to reduce vision impairment are pushing adoption of DR diagnostics and treatment.
Technological innovations: Advances in both therapeutic options (drug delivery systems, implants) and diagnostic tools (AI, imaging modalities) are improving outcomes, reducing burdens (e.g. of frequent treatments), and making diagnosis more accessible.
Increasing healthcare spending and infrastructure development: Growth in ophthalmology centers, better diagnostic equipment, improvements in treatment delivery, and more resources in emerging markets help expand market reach.
Request for a sample copy of this report: https://www.imarcgroup.com/diabetic-retinopathy-market/requestsample
Industry Trends and Drivers:
Rising prevalence of diabetes: As the global population continues to age and obesity rates increase, more individuals are developing type 1 and type 2 diabetes, which are key risk factors for diabetic retinopathy. Diabetic retinopathy occurs when chronic high blood sugar levels cause damage to the blood vessels in the retina, potentially leading to blindness if left untreated. According to global health organizations, the number of people with diabetes is expected to rise significantly in the coming years, particularly in developing countries where urbanization and lifestyle changes are contributing to higher rates of the disease. As the number of diabetic patients grows, so does the need for effective management and treatment of complications such as diabetic retinopathy, strengthening the market demand.
Advancements in diagnostic technologies: Early detection is critical for preventing vision loss caused by diabetic retinopathy, and innovations in diagnostic tools are improving the accuracy and accessibility of screening methods. For example, the development of non-invasive imaging techniques, such as optical coherence tomography (OCT) and fundus photography, has revolutionized the way diabetic retinopathy is diagnosed. These technologies allow for detailed visualization of retinal structures, enabling early identification of disease progression. Furthermore, artificial intelligence (AI) and machine learning algorithms are being integrated into diagnostic systems to automate the detection of diabetic retinopathy from retinal images, increasing the efficiency and accuracy of screening processes and thereby aiding the market growth.
Increasing awareness of the importance of early diagnosis and treatment: Public health initiatives, medical campaigns, and educational programs are raising awareness about the risks of untreated diabetic retinopathy and the benefits of regular eye examinations for diabetic patients. Healthcare providers are emphasizing the importance of annual eye screenings to detect retinopathy before symptoms become severe, particularly among high-risk populations. Additionally, the availability of effective treatments such as anti-vascular endothelial growth factor (VEGF) injections, laser therapy, and vitrectomy surgery is encouraging more patients to seek timely interventions. As awareness about diabetic retinopathy and the available treatments grows, more patients are being diagnosed and treated at earlier stages, further contributing to the demand for related medical products and services.
Diabetic Retinopathy Market Report Segmentation:
Breakup By Type:
- Proliferative Diabetic Retinopathy
- Non-proliferative Retinopathy
Non-proliferative retinopathy accounts for the majority of shares, as is the early stage of diabetic retinopathy, it is making it more commonly diagnosed and treated than the more severe proliferative form.
Breakup By Treatment Type:
- Anti VEGF Drugs
- Steroid Implants
- Laser Surgeries
- Vitrectomy
Anti-VEGF drugs dominate the market due to their effectiveness in halting disease progression and preventing vision loss in patients with diabetic retinopathy.
Breakup By End User:
- Hospitals and Pharmacies
- Eye Clinics
- Ambulatory Surgical Centres (ASCs)
- Others
Hospitals and pharmacies represent the majority of shares as they are the primary points of care (POC) for the administration of treatments and management of diabetic retinopathy, offering comprehensive services.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America holds the leading position due to the high prevalence of diabetes, advanced healthcare infrastructure, and strong adoption of cutting-edge diabetic retinopathy treatments.
Top Diabetic Retinopathy Market Leaders:
The diabetic retinopathy market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies.
Some of the key players in the market are:
- Alimera Sciences
- Allergan PLC
- Ampio Pharmaceuticals
- Bayer Healthcare
- BCN Peptides
- Genentech
- Kowa Group
- Novartis AG
- Regeneron Pharmaceuticals Inc. and Sirnaomics Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Ask An Analyst: https://www.imarcgroup.com/request?type=report&id=1932&flag=C
About Us:
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302
